ITP Support Association/LinkedIn
Aug 10, 2026, 13:36
Ianalumab and the Changing Landscape of ITP Treatment – ITP Support Association
ITP Support Association shared a post on LinkedIn:
“We asked Tung Le at Imperial College Hammersmith Hospital what Novartis have been working on. The answer: Ianalumab, studied across four trials between 2023 and 2025, each looking at a different stage of ITP:
- First-line – newly diagnosed patients, started within 28 days of diagnosis
- Second-line – patients who hadn’t responded to first-line therapy
- Refractory – patients who’d already been through multiple lines of treatment
Recruitment for these particular trials has now closed, but patients who took part are still being followed up, some for two to three years so far, helping researchers understand the longer-term picture.
Research like this is how new treatment options eventually make their way to patients. Curious what’s currently recruiting?
We keep an up-to-date list on our website.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Sep 25, 2026, 10:49Shefina S: From Presenting to Hosting at TRANSCON 2026
-
Sep 25, 2026, 10:37Michelle Leona Cecil: Hemophilia Advocacy and the Power of Community
-
Sep 25, 2026, 10:13Michael Baria: Platelet Concentration and PRP Outcomes in Partial Rotator Cuff Tears
-
Sep 25, 2026, 09:49Haley Coleman: Volunteering to Support Hemophilia Awareness
-
Sep 25, 2026, 08:55Hitarth Mehta: BHMS Students Gain Practical Exposure to Haemophilia Diagnosis
-
Sep 25, 2026, 07:25Varun Capoor: How Therapeutic Apheresis and Transfusion Medicine Can Complement Clinical Management in SCD
-
Sep 25, 2026, 07:14Manshi Kesharwani: SAK-GQDs Modulate Thrombus Burden and Endothelial Function in Deep Vein Thrombosis
-
Sep 25, 2026, 06:20Farjah Hassan Algahtani: How Can We Better Identify Patients at Risk of Blood Clots after Metabolic and Bariatric Surgery?
-
Sep 25, 2026, 05:59Carla Lewis: Kids Conquering Sickle Disease Joins Nemours Children’s Hospital for 2nd Annual Awareness Event